We are live on
!
Find out more
Fayez Sarofim & Co Portfolio holdings
AUM
$39.1B
1-Year Est. Return
15.14%
This Fund
S&P 500
This Quarter
Est. Return
+5.93%
1 Year Est. Return
+15.14%
3 Year Est. Return
+57.14%
5 Year Est. Return
+86.44%
10 Year Est. Return
+860.5%
AUM
$28.6B
AUM Growth
+$1.5B
(+5.6%)
Cap. Flow
+$262M
Cap. Flow
% of AUM
0.92%
Top 10 Holdings %
Top 10 Hldgs %
43.01%
Holding
291
New
10
Increased
102
Reduced
100
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$67.8M |
| 2 |
Microsoft
MSFT
|
+$65M |
| 3 |
Apple
AAPL
|
+$45M |
| 4 |
Amazon
AMZN
|
+$42.8M |
| 5 |
Philip Morris
PM
|
+$40.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$56.2M |
| 2 |
Meta Platforms (Facebook)
META
|
+$38.9M |
| 3 |
American Express
AXP
|
+$32.9M |
| 4 |
Morgan Stanley
MS
|
+$32.6M |
| 5 |
Procter & Gamble
PG
|
+$31.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.05% |
| 2 | Consumer Staples | 18.27% |
| 3 | Financials | 17.61% |
| 4 | Energy | 12.56% |
| 5 | Healthcare | 11.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Invesco
IVZ
$14B
| $175K | ﹤0.01% |
10,691
| – | – |
|
277
Plains GP Holdings
PAGP
$5.02B
| $151K | ﹤0.01% |
11,500
| – | – |
|
|
ONTF
278
DELISTED
ON24
ONTF
| $130K | ﹤0.01% |
14,882
| – | – |
|
279
Viatris
VTRS
$19B
| $103K | ﹤0.01% |
10,666
+155
| +1% | +$1.72K |
|
280
W&T Offshore
WTI
$497M
| $60.2K | ﹤0.01% |
11,858
-29,055
| -71% | -$162K |
|
|
PLXP
281
DELISTED
PLx Pharma Inc. Common Stock
PLXP
| $1.79K | ﹤0.01% |
13,729
| – | – |
|
282
iShares MSCI ACWI ETF
ACWI
$33.3B
| – | – |
-4,159
| Closed | -$353K |
|
283
Cigna
CI
$72.7B
| – | – |
-667
| Closed | -$221K |
|
284
Cohen & Steers
CNS
$4.34B
| – | – |
-50,000
| Closed | -$3.23M |
|
285
Devon Energy
DVN
$49.7B
| – | – |
-3,318
| Closed | -$204K |
|
|
GRFS
286
Grifois
GRFS
$5.33B
| – | – |
-111,452
| Closed | -$947K |
|
|
MTR
287
Mesa Royalty Trust
MTR
$5.33M
| – | – |
-9,500
| Closed | -$209K |
|
288
Omnicom Group
OMC
$22.6B
| – | – |
-3,512
| Closed | -$286K |
|
|
SCHW
289
Charles Schwab
SCHW
$187B
| – | – |
-5,363
| Closed | -$447K |
|
290
Toyota
TM
$222B
| – | – |
-1,680
| Closed | -$229K |
|
291
Warner Bros
WBD
$66.2B
| – | – |
-58,104
| Closed | -$551K |
|
Similar funds
HF
Fayez Sarofim & Co's Q1 2023 Portfolio in Review
As of Q1 2023, Fayez Sarofim & Co held 291 positions worth $28.6B, up 5.6% from $27.1B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Fayez Sarofim & Co's Q1 2023 filing shows 10 new, 102 increased, 100 reduced and 10 closed positions. Its largest new stake was MSCI: 9,600 shares worth $5.37M. The largest sale was Johnson & Johnson, an estimated $56.2M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Consumer Staples and Financials.
- Fayez Sarofim & Co's largest Q1 2023 buy was MSCI: 9,600 shares worth $5.37M.
- Fayez Sarofim & Co added most to AstraZeneca in Q1 2023, an estimated $67.8M increase.
- Fayez Sarofim & Co's biggest Q1 2023 reduction was Johnson & Johnson, cutting an estimated $56.2M.
- Fayez Sarofim & Co fully exited Cohen & Steers in Q1 2023, selling an estimated $3.23M.
- Fayez Sarofim & Co's ten largest holdings make up 43% of its $28.6B portfolio in Q1 2023.
- Fayez Sarofim & Co opened 10 new positions and closed 10 in Q1 2023.
- Fayez Sarofim & Co's portfolio value rose 5.6% quarter-over-quarter to $28.6B.
Based on Fayez Sarofim & Co's 13F filing for Q1 2023, filed 11 May 2023.